Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpainsymman.2009.11.311 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of low-dose amitriptyline and mirtazapine in patients with insomnia disorder with sleep maintenance problems: a randomised, double-blind, placebo-controlled trial in general practice (DREAMING).
Br J Gen Pract
January 2025
Amsterdam UMC Locatie Meibergdreef, Vrije Universiteit, Department of General Practice, Amsterdam, Netherlands.
Background: Low-dose amitriptyline and mirtazapine are widely prescribed off-label for insomnia disorder. However, evidence from placebo-controlled studies is lacking.
Aim: To assess the effectiveness of low-dose mirtazapine and amitriptyline in patients with insomnia disorder.
Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms.
BMC Med
January 2025
Lurie Center for Autism, Massachusetts General Hospital, Lexington, MA, 02421, USA.
Background: The prevalence of autism spectrum disorder (ASD) has surged, with an estimated 1 in 36 eight-year-olds in the United States meeting criteria for ASD in 2020. Autistic individuals face elevated rates of co-occurring medical, psychiatric, and behavioral conditions compared to non-autistic individuals. The rising ASD-patient demand is increasingly outpacing the capacity of ASD-specialty clinics, resulting in urgent need for autism-competent providers in general practice settings.
View Article and Find Full Text PDFRandomized clinical trial: the effects of mirtazapine in functional dyspepsia patients.
Therap Adv Gastroenterol
January 2025
Center of Health Management, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, Shandong 250012, China.
Background: Functional dyspepsia (FD) is one of the most common gastrointestinal disorders worldwide. Currently, anti-gastric drugs, gastric acid inhibitors, prokinetic drugs, and mucosal protective drugs are widely used in FD patients, however, only a small proportion of patients benefit from these drugs. Studies reported mirtazapine may improve symptoms of FD patients but the efficacy and safety of mirtazapine in the treatment of FD is unclear.
View Article and Find Full Text PDFPeripheral Edema as an Adverse Drug Reaction to Mirtazapine in an Oral Cavity Cancer Patient Receiving Palliative Care at Tertiary Care Centre: A Case Report.
J Pain Palliat Care Pharmacother
January 2025
Department of Palliative Medicine, S.M.S. Medical College, Jaipur, Rajasthan, India.
Mirtazapine is a selective serotonergic antidepressant that functions by blocking adrenergic alpha2-autoreceptors and heteroreceptors and inhibiting 5-HT2 and 5-HT3 receptors. It is a noradrenergic drug. Mirtazapine has anxiolytic or sleep-quality-improving effects, aggravates appetite-stimulation, and has stomach emptying functions.
View Article and Find Full Text PDFEffectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews.
Rheumatology (Oxford)
December 2024
Division of Preventive Medicine, Department of Medicine, University of Alberta, Edmonton AB, Canada.
Objectives: To summarise and evaluate Cochrane reviews of pharmacological therapies for adults with fibromyalgia syndrome (FMS) pain.
Methods: Systematic search of Cochrane Database of Systematic Reviews to May 2024. Generic quality assessment used AMSTAR-2 criteria, validity checks of potentially critical factors in evaluation of analgesic efficacy, and assessment of susceptibility of results to publication bias.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!